GHRP-2
Second-generation hexapeptide GHRP with superior potency. Approved in Japan as Pralmorelin.
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Chain
GHRP-2
COMPOUND
1 Research Goal
• Muscle & Tissue Growth
Evidence Strength
2 articles sourced
Knowledge Graph
(3 connections)Research Evidence
(2)Growth Hormone Secretagogues and IGF-1 Axis Research
Examination of GHRH, GHRP, and ghrelin mimetic mechanisms in GH secretion and IGF-1 axis research.
Peptide Synergy: Growth Hormone Secretagogue Stacking
Evidence-based review of GH secretagogue peptide synergy, examining pulsatile GH release, receptor mechanisms, and combination protocols.
Overview
GHRP-2 (also known as Pralmorelin) is a second-generation synthetic hexapeptide GHRP (D-Ala-D-beta-naphthyl-Ala-L-Trp-D-Phe-L-Lys-NH2) that offers improved potency compared to GHRP-6. Approved in Japan under the brand name GHRP-2 for the diagnosis of growth hormone deficiency, GHRP-2 represents the evolution of GHRP research toward more potent and selective compounds.
Mechanism of Action
GHRP-2 acts as an agonist at the ghrelin receptor (GHS-R1a), stimulating growth hormone release from the anterior pituitary. Compared to GHRP-6, GHRP-2 demonstrates greater potency in stimulating GH release while producing less hunger stimulation. Like other GHRPs, GHRP-2 acts through a pathway distinct from GHRH, producing synergistic effects when combined with GHRH or GHRH analogs. GHRP-2 also stimulates ACTH and cortisol release, though to a lesser degree than GHRP-6 in some studies.
Research Highlights
Clinical studies demonstrated GHRP-2's superior potency compared to GHRP-6 in stimulating GH release, with effective doses lower than those of GHRP-6. Research established its efficacy in diagnosing growth hormone deficiency, leading to approval in Japan. Studies explored its potential in treating growth hormone deficiency, catabolic states, and as a research tool for GH axis studies. Research demonstrated synergistic effects with GHRH analogs, producing GH elevations greater than either compound alone.
Dosage & Administration
In research, GHRP-2 has been administered via subcutaneous injection at doses of 100-150 mcg per administration, typically 2-3 times daily. For research use only (RUO).
Safety Profile
Common side effects include increased appetite (less pronounced than GHRP-6), water retention, and transient cortisol elevation. Mild injection site reactions may occur. As an approved drug in Japan, GHRP-2 has clinical safety data, though long-term data is limited. Not approved by the FDA in the United States.
References
Bowers CY, et al. GHRP-2 and GH release. J Clin Endocrinol Metab. 1992. Arvat E, et al. GHRP-2 clinical studies. J Endocrinol Invest. 1997. Japanese PMDA GHRP-2 approval information. All content is for educational and research purposes only.
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.